{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T05:50:40Z","timestamp":1698213040592},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T00:00:00Z","timestamp":1153267200000},"content-version":"vor","delay-in-days":6927,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[1987,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Advanced squamous cell carcinoma of the head and neck, lung, esophagus, and uterine cervix is still a challenging cancer to the medical practice. We have treated 23 such patients with a combination of cis\u2010platinum, vincristine, and peplomycin. Cis\u2010platinum was given at a dose of 60 mg\/m<jats:sup>2<\/jats:sup> on day 1, and 1.0 mg\/m<jats:sup>2<\/jats:sup> of vincristine was given on day 3, followed 6 hours later by peplomycin 10 mg\/day by continuous infusion iv or sc over the next 5 days. This combination was given every 3 weeks. The overall response rate was 71% for 17 evaluable patients, including one complete response. The median duration of response and survival was 2 and 5 months, respectively. Six other patients with esophageal and cervical carcinoma were treated with two cycles of this combination followed by radical radiation therapy or surgery. Five of them achieved significant response prior to radical treatment. Major side effects were nausea, vomiting, alopecia, and mild myelotoxicity, which were acceptable. This regimen, with a high response rate and acceptable toxicity, warrants further investigation.<\/jats:p>","DOI":"10.1002\/jso.2930350406","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T11:16:07Z","timestamp":1171970167000},"page":"241-244","source":"Crossref","is-referenced-by-count":4,"title":["Phase II trial of cis\u2010diamminedichloroplatinum (cis\u2010platinum), vincristine, and peplomycin for advanced squamous cell carcinoma"],"prefix":"10.1002","volume":"35","author":[{"given":"Kazuo","family":"Tamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Tateyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritaka","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Seita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,19]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"647","article-title":"Clinical studies of platinum coordination compounds in the treatment of various malignant diseases","volume":"59","author":"Hill JM","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_3_2","first-page":"1341","article-title":"High\u2010Dose cisplatin with fluid and mannitol\u2010Induced diuresis in advanced lung cancer: A phase II clinical trial of the EORTC lung cancer working party (Belgium)","volume":"64","author":"De Jager R","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_4_2","first-page":"359","article-title":"Cis\u2010Dichlorodiammineplatinum (II) in the treatment of epidermoid carcinoma of the head and neck","volume":"61","author":"Wittes RE","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810815)48:4<899::AID-CNCR2820480406>3.0.CO;2-6"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197711)40:5<2027::AID-CNCR2820400506>3.0.CO;2-A"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197610)38:4<1503::AID-CNCR2820380410>3.0.CO;2-9"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(83)90102-6"},{"key":"e_1_2_1_9_2","first-page":"1005","article-title":"Chemotherapy for advanced cervical cancer with methotrexate, bleomycin, and cisdichloro\u2010Diammineplatinum (II)","volume":"63","author":"Vogl SE","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00254598"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820315)49:6<1174::AID-CNCR2820490618>3.0.CO;2-W"},{"key":"e_1_2_1_12_2","first-page":"311","volume-title":"Bleomycin: Current Status and New Developments","author":"Matsuda A","year":"1978"},{"key":"e_1_2_1_13_2","first-page":"1498","article-title":"Pepleomycin","volume":"7","author":"Inuyama Y","year":"1980","journal-title":"Jpn J Cancer Chemother"},{"key":"e_1_2_1_14_2","first-page":"205","article-title":"Bleomycin, cisplatin, vincristine, and methotrexate in advanced non\u2010Small cell bronchogenic carcinoma","volume":"66","author":"Rosenthal CJ","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-198008000-00003"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(83)80022-X"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(82)90417-2"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(80)90207-X"},{"key":"e_1_2_1_19_2","first-page":"313","article-title":"Mitomycin\u2010C, bleomycin, vincristine, and cis\u2010Platinum in the treatment of advance, recurrent squamous cell carcinoma of the cervix","volume":"4","author":"Alberts DS","year":"1981","journal-title":"Cancer Clin Trials"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197612)38:6<2222::AID-CNCR2820380605>3.0.CO;2-R"},{"key":"e_1_2_1_21_2","first-page":"146","article-title":"Mitomycin C, vincristine, and bleomycin therapy for advanced cervical cancer","volume":"52","author":"Baker LH","year":"1978","journal-title":"Obstet Gynecol"},{"key":"e_1_2_1_22_2","first-page":"234","volume-title":"Adriamycin","author":"Levi JA","year":"1984"},{"key":"e_1_2_1_23_2","first-page":"1258","article-title":"Vincristine treatment of advanced cancer: A cooperative study of 392 cases","volume":"33","author":"Holland JF","year":"1973","journal-title":"Cancer Res"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.2.75"},{"key":"e_1_2_1_25_2","first-page":"2372","article-title":"Plasma concentration of peplomycin following intravenous infusion and subcutaneous infusion in patients with malignancies","volume":"11","author":"Sampi K","year":"1984","journal-title":"Jpn J Cancer Chemother"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.2930350406","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.2930350406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T17:57:45Z","timestamp":1697911065000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.2930350406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1987,8]]}},"alternative-id":["10.1002\/jso.2930350406"],"URL":"https:\/\/doi.org\/10.1002\/jso.2930350406","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987,8]]}}}